-$0.05 EPS Expected for AxoGen, Inc Common Stock (AXGN) This Quarter

Wall Street analysts expect that AxoGen, Inc Common Stock (NASDAQ:AXGN) will announce ($0.05) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for AxoGen, Inc Common Stock’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.07). AxoGen, Inc Common Stock reported earnings per share of ($0.06) during the same quarter last year, which would indicate a positive year over year growth rate of 16.7%. The company is scheduled to issue its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that AxoGen, Inc Common Stock will report full-year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.22). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.16) to ($0.07). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover AxoGen, Inc Common Stock.

AxoGen, Inc Common Stock (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $20.58 million during the quarter, compared to the consensus estimate of $21.25 million. AxoGen, Inc Common Stock had a negative net margin of 24.96% and a negative return on equity of 26.50%. The business’s revenue was up 35.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.04) earnings per share.

Several analysts recently weighed in on AXGN shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective (up from $37.00) on shares of AxoGen, Inc Common Stock in a report on Tuesday, May 1st. JMP Securities lifted their price objective on AxoGen, Inc Common Stock from $34.00 to $43.00 and gave the company a “market outperform” rating in a report on Tuesday, May 1st. ValuEngine upgraded AxoGen, Inc Common Stock from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Leerink Swann restated an “outperform” rating and issued a $70.00 price objective on shares of AxoGen, Inc Common Stock in a report on Tuesday, June 26th. Finally, BidaskClub downgraded AxoGen, Inc Common Stock from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. AxoGen, Inc Common Stock currently has a consensus rating of “Buy” and an average price target of $41.29.

Shares of AXGN stock traded down $0.50 on Wednesday, hitting $39.40. The stock had a trading volume of 394,142 shares, compared to its average volume of 640,349. The company has a market capitalization of $1.45 billion, a P/E ratio of -127.10 and a beta of 0.01. AxoGen, Inc Common Stock has a one year low of $15.35 and a one year high of $56.85.

In other news, Director Amy Mcbride Wendell acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average cost of $36.89 per share, for a total transaction of $184,450.00. Following the completion of the acquisition, the director now directly owns 18,333 shares of the company’s stock, valued at approximately $676,304.37. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.86% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. raised its holdings in AxoGen, Inc Common Stock by 844.4% in the second quarter. Meeder Asset Management Inc. now owns 2,427 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 2,170 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $156,000. Bank of Montreal Can bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $180,000. Jane Street Group LLC bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $201,000. Finally, Quantitative Systematic Strategies LLC bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $207,000. Institutional investors and hedge funds own 81.02% of the company’s stock.

About AxoGen, Inc Common Stock

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

See Also: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on AxoGen, Inc Common Stock (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen, Inc Common Stock (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply